Active Surveillance for Prostate Cancer: Progress and Promise
- 20 September 2011
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (27) , 3669-3676
Abstract
Widespread prostate-specific antigen (PSA) –based screening and aggressive treatment of prostate cancer have reduced mortality rates substantially, but both remain controversial in large part because of high rates of overdiagnosis and overtreatment of otherwise indolent tumors. Active surveillance—or close monitoring of PSA levels combined with periodic imaging and repeat biopsies—is gaining acceptance as an alternative initial management strategy for men with low-risk prostate cancer. In reported series, rates of progression to active treatment with intermediate-term follow-up have ranged from 14% to 41%, and likelihood of subsequent cure with surgery or radiation does not seem to be compromised by an initial trial of surveillance. Two related challenges to broader acceptance of surveillance are better characterization at time of diagnosis of the risk of progression (including likelihood that given tumor may have been undersampled by diagnostic biopsy) and validation of optimal end points once surveillance begins. Both are subjects of intense ongoing investigation, with emerging biomarkers and novel imaging tests expected to facilitate decision making substantially. Recent reports have suggested active surveillance can be a cost-effective approach and preserve quality of life, but these questions must be assessed more definitively in prospective cohorts. Ultimately, by minimizing the harms of overtreating low-risk prostate cancer, active surveillance may help settle the controversy surrounding prostate cancer screening and management.Keywords
This publication has 74 references indexed in Scilit:
- Role of Prostate Specific Antigen and Immediate Confirmatory Biopsy in Predicting Progression During Active Surveillance for Low Risk Prostate CancerJournal of Urology, 2011
- Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate CancerJAMA, 2010
- Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studiesEuropean Journal of Cancer, 2010
- Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP miceJournal of Magnetic Resonance, 2010
- Outcomes of Localized Prostate Cancer Following Conservative ManagementJAMA, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle interventionProceedings of the National Academy of Sciences, 2008
- Does the Level of Prostate Cancer Risk Affect Cancer Prevention with Finasteride?Urology, 2008
- Quantifying the role of PSA screening in the US prostate cancer mortality declineCancer Causes & Control, 2007
- Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and TreatmentJournal of Urology, 2007